Fig. 5.

Human leucocyte antigen (HLA) class I recognition of the antibodies secreted by the hybridoma cell line HML16. (a) Illustration of the amino acid composition of HLA class I alleles recognized by the antibodies secreted by the hybridoma cell line. Alleles are ranked according to the decreasing mean fluorescent intensity (MFI) of the alloantibody. The MFI of the major alleles correlate with the differences in the amino acids among different alleles: MFI of antibodies is high against B*8101, B*0702, B*4201 and B*6701, low against B*2708, B*2705, B*5501, B*5601 and B*8201. (b–e) The effects of IVIg (b,c) and anti-HLA-E monoclonal antibody (mAb) Terasaki Foundation Laboratory (TFL)-007a (d,e) on the secretion of anti-HLA-B IgG antibodies by the hybridoma are compared with medium control and/or with mouse IgG control. The therapeutic preparations of IVIg from GamaSTAN and Gamunex-C had least impact on the secretion both antibodies (b,c). In contrast, anti-HLA-E mAb TFL-007a significantly (P² < 0·0001) suppressed the IgG secretion against HLA-B*0702 (d) and B*8101 (e).